NLS Sobi

Careers article - April 6, 2022

Sobi to cease ReFacto manufacturing

Sobi has announced that its contract with Pfizer for the manufacture of drug substance for ReFacto AF/Xyntha (ReFacto) has been amended due to clarity of final order volumes and will now expire in the first quarter of 2024, earlier than the previous expiry date at the end of 2025. Manufacturing of drug substance for ReFacto […]

Pharma Business - February 28, 2022

Sobi’s Gamifant recommended for approval in China

The Center for Drug Evaluation (CDE) has recommended approval of Gamifant to the National Medical Products Administration of China (NMPA). The indication is for treatment of adult and paediatric (newborn and older) patients with primary haemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent or progressive disease or intolerance to conventional HLH therapy. “We are gratified that CDE […]

COVID-19 - December 20, 2021

Sobi’s Kinaret receives positive opinion from the CHMP

The Committee for Medicinal Products for Human Use of the EMA has adopted a positive opinion of Kineret for the treatment of COVID-19 in adult patients with pneumonia requiring supplemental oxygen who are at risk of progressing to severe respiratory failure determined by plasma concentration of soluble urokinase plasminogen activator receptor ≥ 6ng/ml. EMA has […]

Acquisition - December 5, 2021

Advent withdraws its Sobi bid

The company in September agreed to an 8 billion USD takeover by Advent and Aurora, an investment vehicle of Singapore’s GIC Pte Ltd, through Agnafit Bidco. “Since the acceptance level condition has not been fulfilled, Agnafit Bidco hereby withdraws the offer,” Agnafit Bidco said in a statement. Commenting on the bid process, the Chairman of […]

Acquisition - October 26, 2021

Agnafit Bidco extends the acceptance period for the Sobi offer

Following receipt of all regulatory approvals, Agnafit Bidco extends the acceptance period for the public offer to the shareholders of Sobi and announces its intention not to increase the price of SEK 235 per share in the Offer. On 2 September 2021, Advent International Corporation1 and Aurora Investment Pte Ltd2, an affiliate of GIC Pte […]

Pharma Business - October 22, 2021

Sobi’s Aspaveli receives positive CHMP opinion

Swedish Orphan Biovitrum  (Sobi) and Apellis Pharmaceuticals have announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion recommending the marketing authorisation of Aspaveli (pegcetacoplan) for the treatment of adults with paroxysmal nocturnal haemoglobinuria (PNH) who are anaemic after treatment with a C5 inhibitor […]

We Value Your Privacy

This site uses cookies

We use cookies to improve your experience on our site. By clicking "accept," you agree to our use of cookies.

Read more about our privacy policy

Only necessary
Accept All
Manage Cookies

Manage Cookies

functional

The "Functional" cookie category includes cookies that are essential for the smooth operation of our website and to enhance your browsing experience. These cookies enable various functionalities that make our site more user-friendly and efficient.

market

The "Market" cookie category encompasses cookies used to analyze and improve our marketing efforts. These cookies help us understand how you interact with our website and provide us with insights to optimize our content and advertisements, ensuring they are relevant to your interests.

personal

The "Personal" cookie category includes cookies that enhance the user experience by storing information about your preferences and interactions on our site. This allows us to tailor content and recommendations to your individual needs, providing a more personalized and engaging experience.